BiotechTube

Palonosetron (Aloxi) and Dexamethasone

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Brain Cancer

Conditions

Brain Cancer

Trial Timeline

May 1, 2008 → Jan 1, 2013

NCT ID
NCT00636805

About Palonosetron (Aloxi) and Dexamethasone

Palonosetron (Aloxi) and Dexamethasone is a phase 2 stage product being developed by Eisai for Brain Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00636805. Target conditions include Brain Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00636805Phase 2Terminated

Competing Products

20 competing products in Brain Cancer

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Duloxetine + Sugar pillEli LillyPhase 2
52
Neurosteroid enantiomerOragenicsPhase 2
44
Patritumab deruxtecanDaiichi SankyoPhase 2
52
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
33
Eribulin MesylateEisaiPhase 1
33
Pembrolizumab + LenvatinibEisaiPhase 2
52
GLIADELEisaiPhase 2
52
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastimEli LillyPhase 1
33
abemaciclib + abemaciclibEli LillyPhase 2
52
JNJ-17299425Johnson & JohnsonPhase 2
52
ABT-888AbbViePhase 1
33
Veliparib + PlaceboAbbViePhase 2
52
Iressa (Gefitinib)AstraZenecaPhase 2
52
Trastuzumab deruxtecanAstraZenecaPhase 2
52
ExenatideAstraZenecaApproved
85
AZD5213AstraZenecaPhase 1
33
VorinostatMerckPhase 1
33

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85